Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. [PDF]
, 2016 IntroductionTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of RA, and improve physical ...
DeMasi, Ryan +6 more
core +9 more sources
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts [PDF]
, 2019 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Objectives To assess predictive factors for rheumatoid arthritis interstitial lung disease (RA-ILD) in two early ...
Busby, Amanda +7 more
core +2 more sources
Treatment recommendations for psoriatic arthritis [PDF]
, 2008 Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.
Boehncke, Wolf-Henning +14 more
core +2 more sources
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. [PDF]
, 2009 Contains fulltext : 80544.pdf (publisher's version ) (Closed ...
Choy, E. +11 more
core +1 more source
What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis [PDF]
, 2020 Introduction: To determine patient and rheumatologist preferences for rheumatoid arthritis (RA) treatment attributes in Spain and to evaluate their attitude towards shared decision-making (SDM).
Comellas, M. +10 more
core +2 more sources
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy [PDF]
, 2015 Objective: To evaluate associations between lipid levels, inflammation, and rheumatoid arthritis (RA) disease activity, at baseline and during treatment, with the risk of major adverse cardiovascular events (MACE) in tocilizumab‐treated patients with RA.
Bathon, Joan M. +7 more
core +1 more source
Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]
, 2019 Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro +5 more
core +3 more sources
Antirheumatic drugs and reproduction in women and men with chronic arthritis. [PDF]
, 2015 The impact of rheumatic disease on fertility and reproduction can be remarkable. Many disease-related factors can influence patients' sexual functioning, perturb fertility and limit family planning. Antirheumatic pharmacological treatment can also have a
Agosti, M +4 more
core +1 more source
Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. [PDF]
, 2009 ObjectiveC-reactive protein (CRP) levels>3 mg/L and>10 mg/L are associated with high and very high cardiovascular risk, respectively, in the general population.
Graf, Jonathan +3 more
core +4 more sources
Metabolic Consequences of Rheumatoid Arthritis
Arthritis Care &Research, EarlyView.Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry +2 more
wiley +1 more source